Bellus Health (OTCMKTS:BLUSF) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.

Bellus Health (OTCMKTS BLUSF) traded down $0.01 during trading on Friday, reaching $0.32. 14,000 shares of the company traded hands, compared to its average volume of 16,353. Bellus Health has a 12-month low of $0.18 and a 12-month high of $0.36.

TRADEMARK VIOLATION WARNING: “ValuEngine Downgrades Bellus Health (BLUSF) to Sell” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at

Bellus Health Company Profile

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company’s pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough.

Receive News & Stock Ratings for Bellus Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health Inc. and related stocks with our FREE daily email newsletter.